The endocrine manifestations of anorexia nervosa: Mechanisms and management

Nature Reviews Endocrinology

Volumn 13, Issue 3, 2017, Pages 174-186

  Schorr, Melanie ^a,b   Miller, Karen K ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; BISPHOSPHONIC ACID DERIVATIVE; ESTROGEN; GESTAGEN; NEUROHYPOPHYSIS HORMONE; ORAL CONTRACEPTIVE AGENT; PARATHYROID HORMONE[1-34]; PRASTERONE; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN C; TESTOSTERONE; GROWTH HORMONE; LEPTIN;

ANOREXIA NERVOSA; BONE DENSITY; BONE DISEASE; BONE STRUCTURE; CLINICAL RESEARCH; COMORBIDITY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; ENDOCRINE DISEASE; ENDOCRINE SYSTEM; FEMALE; FOOD INTAKE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; HYPOTHALAMUS HYPOPHYSIS THYROID SYSTEM; KIDNEY FUNCTION; MENSTRUATION; MENTAL DISEASE; REVIEW; WEIGHT GAIN; BLOOD; DISEASE MANAGEMENT; ENDOCRINE SYSTEM DISEASES; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MALE; METABOLISM;

ADIPOKINES; ANOREXIA NERVOSA; DISEASE MANAGEMENT; ENDOCRINE SYSTEM DISEASES; FEMALE; GROWTH HORMONE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; LEPTIN; MALE; PITUITARY-ADRENAL SYSTEM;

EID: 84994081864     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2016.175     Document Type: Review

References (183)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (American Psychiatric Publishing, 2013).
2. Miller, K. K. et al. Preservation of neuroendocrine control of reproductive function despite severe undernutrition. J. Clin. Endocrinol. Metab. 89, 4434-4438 (2004).
3. Currin, L., Schmidt, U., Treasure, J. & Jick, H. Time trends in eating disorder incidence. Br. J. Psychiatry 186, 132-135 (2005).
4. Smink, F. R. E. et al. Three decades of eating disorders in Dutch primary care: decreasing incidence of bulimia nervosa but not of anorexia nervosa. Psychol. Med. 46, 1189-1196 (2016).
5. Lucas, A. R., Crowson, C. S., O'Fallon, W. M. & Melton, L. J. The ups and downs of anorexia nervosa. Int. J. Eat. Disord. 26, 397-405 (1999).
6. Smink, F. R. E., van Hoeken, D., Oldehinkel, A. J. & Hoek, H. W. Prevalence and severity of DSM-5 eating disorders in a community cohort of adolescents. Int. J. Eat. Disord. 47, 610-619 (2014).
7. Mancuso, S. G. et al. Classification of eating disorders: comparison of relative prevalence rates using DSM-IV and DSM-5 criteria. Br. J. Psychiatry 206, 519-520 (2015).
8. Larrañaga, A., Docet, M. F. & García-Mayor, R. V. High prevalence of eating disorders not otherwise specified in northwestern Spain: population-based study. Soc. Psychiatry Psychiatr. Epidemiol. 47, 1669-1673 (2012).
9. Lucas, A. R., Beard, C. M., O'Fallon, W. M. & Kurland, L. T. 50-year trends in the incidence of anorexia nervosa in Rochester, Minn.: a population-based study. Am. J. Psychiatry 148, 917-922 (1991).
10. Miller, K. K. Endocrine dysregulation in anorexia nervosa update. J. Clin. Endocrinol. Metab. 96, 2939-2949 (2011).
11. Löwe, B. et al. Long-term outcome of anorexia nervosa in a prospective 21-year follow-up study. Psychol. Med. 31, 881-890 (2001).
12. Fichter, M. M., Quadflieg, N. & Hedlund, S. Twelve-year course and outcome predictors of anorexia nervosa. Int. J. Eat. Disord. 39, 87-100 (2006).
13. Steinhausen, H.-C. The outcome of anorexia nervosa in the 20th century. Am. J. Psychiatry 159, 1284-1293 (2002).
14. Miller, K. et al. Medical findings in outpatients with anorexia nerovsa. Arch. Intern. Med. 165, 561-566 (2005).
15. Vanderschueren, S., Geens, E., Knockaert, D. & Bobbaers, H. The diagnostic spectrum of unintentional weight loss. Eur. J. Intern. Med. 16, 160-164 (2005).
16. Boyar, R. M. et al. Anorexia nervosa - immaturity of the 24-hour luteinizing hormone secretory pattern. N. Engl. J. Med. 291, 861-865 (1974).
17. Katz, J. L., Boyar, R., Roffwarg, H., Hellman, L. & Weiner, H. Weight and circadian luteinizing hormone secretory pattern in anorexia nervosa. Psychosom. Med. 40, 549-567 (1978).
18. Ahima, R. S. et al. Role of leptin in the neuroendocrine response to fasting. Nature 382, 250-252 (1996).
19. Grinspoon, S. et al. Serum leptin levels in women with anorexia nervosa. J. Clin. Endocrinol. Metab. 81, 3861-3863 (1996).
20. Welt, C. K. et al. Recombinant human leptin in women with hypothalamic amenorrhea. N. Engl. J. Med. 351, 987-997 (2004).
21. Gottsch, M. L. et al. A role for kisspeptins in the regulation of gonadotropin secretion in the mouse. Endocrinology 145, 4073-4077 (2004).
22. De Roux, N. et al. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proc. Natl Acad. Sci. USA 100, 10972-10976 (2003).
23. Jayasena, C. N. et al. Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis. J. Clin. Endocrinol. Metab. 94, 4315-4323 (2009).
24. Caronia, L. M. et al. A genetic basis for functional hypothalamic amenorrhea. N. Engl. J. Med. 364, 215-225 (2011).
25. Miller, K. K. et al. Androgens in women with anorexia nervosa and normal-weight women with hypothalamic amenorrhea. J. Clin. Endocrinol. Metab. 92, 1334-1339 (2007).
26. Golden, N. H. et al. Resumption of menses in anorexia nervosa. Arch. Pediatr. Adolesc. Med. 151, 16-21 (1997).
27. Jacoangeli, F. et al. Amenorrhea after weight recover in anorexia nervosa: role of body composition and endocrine abnormalities. Eat. Weight Disord. 11, e20-e26 (2006).
28. Misra, M. et al. Alterations in growth hormone secretory dynamics in adolescent girls with anorexia nervosa and effects on bone metabolism. J. Clin. Endocrinol. Metab. 88, 5615-5623 (2003).
29. Støving, R. K. et al. Jointly amplified basal and pulsatile growth hormone (GH) secretion and increased process irregularity in women with anorexia nervosa: indirect evidence for disruption of feedback regulation within the GH-insulin-like growth factor I axis. J. Clin. Endocrinol. Metab. 84, 2056-2063 (1999).
30. Roth, J., Glick, S. M., Yalow, R. S. & Berson, S. A. Hypoglycemia: a potent stimulus to secretion of growth hormone. Science 140, 987-988 (1963).
31. Counts, D. R., Gwirtsman, H., Carlsson, L. M., Lesem, M. & Cutler, G. B. The effect of anorexia nervosa and refeeding on growth hormone-binding protein, the insulin-like growth factors (IGFs), and the IGF-binding proteins. J. Clin. Endocrinol. Metab. 75, 762-767 (1992).
32. Støving, R. K. et al. Bioactive insulin-like growth factor (IGF) I and IGF-binding protein-1 in anorexia nervosa. J. Clin. Endocrinol. Metab. 92, 2323-2329 (2007).
33. Golden, N. H. et al. Disturbances in growth hormone secretion and action in adolescents with anorexia nervosa. J. Pediatr. 125, 655-660 (1994).
34. Modan-Moses, D. et al. Stunting of growth as a major feature of anorexia nervosa in male adolescents. Pediatrics 111, 270-276 (2003).
35. Modan-Moses, D. et al. Linear growth and final height characteristics in adolescent females with anorexia nervosa. PLoS ONE 7, e45504 (2012).
36. Prabhakaran, R. et al. Determinants of height in adolescent girls with anorexia nervosa. Pediatrics 121, e1517-e1523 (2008).
37. Zhao, T.-J. et al. Ghrelin O-acyltransferase (GOAT) is essential for growth hormone-mediated survival of calorie-restricted mice. Proc. Natl Acad. Sci. USA 107, 7467-7472 (2010).
38. Gahete, M. D., Córdoba-Chacón, J., Luque, R. M. & Kineman, R. D. The rise in growth hormone during starvation does not serve to maintain glucose levels or lean mass but is required for appropriate adipose tissue response in female mice. Endocrinology 154, 263-269 (2013).
39. Nishimura, T., Nakatake, Y., Konishi, M. & Itoh, N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim. Biophys. Acta 1492, 203-206 (2000).
40. Zhang, X. et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57, 1246-1253 (2008).
41. Inagaki, T. et al. Endocrine regulation of the fasting response by PPARα-mediated induction of fibroblast growth factor 21. Cell Metab. 5, 415-425 (2007).
42. Inagaki, T. et al. Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. Cell Metab. 8, 77-83 (2008).
43. Fazeli, P. K., Misra, M., Goldstein, M., Miller, K. K. & Klibanski, A. Fibroblast growth factor-21 may mediate growth hormone resistance in anorexia nervosa. J. Clin. Endocrinol. Metab. 95, 369-374 (2010).
44. Leung, K.-C. Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation. J. Clin. Endocrinol. Metab. 85, 4712-4720 (2000).
45. Gianotti, L. et al. Effects of recombinant human insulin-like growth factor I administration on spontaneous and growth hormone (GH)-releasing hormone-stimulated GH secretion in anorexia nervosa. J. Clin. Endocrinol. Metab. 85, 2805-2809 (2000).
46. Kojima, M. et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402, 656-660 (1999).
47. Misra, M. et al. Secretory dynamics of ghrelin in adolescent girls with anorexia nervosa and healthy adolescents. Am. J. Physiol. Endocrinol. Metab. 289, E347-E356 (2005).
48. Hotta, M. et al. The relationship between bone turnover and body weight, serum insulin-like growth factor (IGF) I, and serum IGF-binding protein levels in patients with anorexia nervosa. J. Clin. Endocrinol. Metab. 85, 200-206 (2000).
49. Argente, J. et al. Multiple endocrine abnormalities of the growth hormone and insulin-like growth factor axis in patients with anorexia nervosa: effect of short-and long-term weight recuperation. J. Clin. Endocrinol. Metab. 82, 2084-2092 (1997).
50. Fazeli, P. K. et al. Effects of recombinant human growth hormone in anorexia nervosa: a randomized, placebo-controlled study. J. Clin. Endocrinol. Metab. 95, 4889-4897 (2010).
51. Boyar, R. et al. Cortisol secretion and metabolism in anorexia nervosa. N. Engl. J. Med. 296, 190-193 (1977).
52. Doerr, P., Fichter, M., Pirke, K. & Lund, R. Relationship between weight gain and hypothalamic pituitary adrenal function in patients with anorexia nervosa. J. Steroid Biochem. 13, 529-537 (1980).
53. Misra, M. et al. Role of cortisol in menstrual recovery in adolescent girls with anorexia nervosa. Pediatr. Res. 59, 598-603 (2006).
54. Biller, B. M., Federoff, H. J., Koenig, J. I. & Klibanski, A. Abnormal cortisol secretion and responses to corticotropin-releasing hormone in women with hypothalamic amenorrhea. J. Clin. Endocrinol. Metab. 70, 311-317 (1990).
55. Misra, M. et al. Alterations in cortisol secretory dynamics in adolescent girls with anorexia nervosa and effects on bone metabolism. J. Clin. Endocrinol. Metab. 89, 4972-4980 (2004).
56. Lawson, E. et al. Hypercortisolemia is associated with severity of bone loss and depression in hypothalamic amenorrhea and anorexia nervosa. J. Clin. Endocrinol. Metab. 94, 4710-4716 (2009).
57. Misra, M. & Klibanski, A. The neuroendocrine basis of anorexia nervosa and its impact on bone metabolism. Neuroendocrinology 93, 65-73 (2011).
58. Arvat, E. et al. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J. Clin. Endocrinol. Metab. 86, 1169-1174 (2001).
59. Mozid, A. M. et al. Ghrelin is released from rat hypothalamic explants and stimulates corticotrophin-releasing hormone and arginine-vasopressin. Horm. Metab. Res. 35, 455-459 (2003).
60. Misra, M. et al. Hormonal determinants of regional body composition in adolescent girls with anorexia nervosa and controls. J. Clin. Endocrinol. Metab. 90, 2580-2587 (2005).
61. Grinspoon, S. et al. Changes in regional fat distribution and the effects of estrogen during spontaneous weight gain in women with anorexia nervosa. Am. J. Clin. Nutr. 73, 865-869 (2001).
62. Lawson, E. A. et al. Increased hypothalamic-pituitary-adrenal drive is associated with decreased appetite and hypoactivation of food-motivation neurocircuitry in anorexia nervosa. Eur. J. Endocrinol. 169, 639-647 (2013).
63. Mayer, L. et al. Body fat redistribution after weight gain in women with anorexia nervosa. Am. J. Clin. Nutr. 81, 1286-1291 (2005).
64. Connan, F. et al. An investigation of hypothalamic-pituitary-adrenal axis hyperactivity in anorexia nervosa: the role of CRH and AVP. J. Psychiatr. Res. 41, 131-143 (2007).
65. Lawson, E. A. et al. Adrenal glucocorticoid and androgen precursor dissociation in anorexia nervosa. J. Clin. Endocrinol. Metab. 94, 1367-1371 (2009).
66. Gordon, C. M. et al. Changes in bone turnover markers and menstrual function after short-term oral DHEA in young women with anorexia nervosa. J. Bone Miner. Res. 14, 136-145 (1999).
67. Zumoff, B. et al. Subnormal plasma dehydroisoandrosterone to cortisol ratio in anorexia nervosa: a second hormonal parameter of ontogenic regression. J. Clin. Endocrinol. Metab. 56, 668-672 (1983).
68. Estour, B. et al. Hormonal profile heterogeneity and short-term physical risk in restrictive anorexia nervosa. J. Clin. Endocrinol. Metab. 95, 2203-2210 (2010).
69. Chopra, I. J. Clinical review 86: euthyroid sick syndrome: is it a misnomer? J. Clin. Endocrinol. Metab. 82, 329-334 (1997).
70. Kaplan, R. Thyroxine abuse. Aust. N. Z. J. Psychiatry 32, 464-465 (1998).
71. Leslie, R. D., Isaacs, A. J., Gomez, J., Raggatt, P. R. & Bayliss, R. Hypothalamo-pituitary-thyroid function in anorexia nervosa: influence of weight gain. Br. Med. J. 2, 526-528 (1978).
72. Ma, X. M. & Lightman, S. L. The arginine vasopressin and corticotrophin-releasing hormone gene transcription responses to varied frequencies of repeated stress in rats. J. Physiol. (Lond.) 510, 605-614 (1998).
73. Rubin, R. T., O'Toole, S. M., Rhodes, M. E., Sekula, L. K. & Czambel, R. K. Hypothalamo-pituitary-adrenal cortical responses to low-dose physostigmine and arginine vasopressin administration: sex differences between major depressives and matched control subjects. Psychiatry Res. 89, 1-20 (1999).
74. Gold, P. W., Kaye, W., Robertson, G. L. & Ebert, M. Abnormalities in plasma and cerebrospinal-fluid arginine vasopressin in patients with anorexia nervosa. N. Engl. J. Med. 308, 1117-1123 (1983).
75. Caregaro, L., Di Pascoli, L., Favaro, A., Nardi, M. & Santonastaso, P. Sodium depletion and hemoconcentration: overlooked complications in patients with anorexia nervosa? Nutrition 21, 438-445 (2005).
76. Bahia, A., Chu, E. S. & Mehler, P. S. Polydipsia and hyponatremia in a woman with anorexia nervosa. Int. J. Eat. Disord. 44, 186-188 (2011).
77. Evrard, F., da Cunha, M. P., Lambert, M. & Devuyst, O. Impaired osmoregulation in anorexia nervosa: a case-control study. Nephrol. Dial. Transplant. 19, 3034-3039 (2004).
78. Spasovski, G. et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Eur. J. Endocrinol. 170, G1-G47 (2014).
79. Mecklenburg, R. S., Loriaux, D. L., Thompson, R. H., Andersen, A. E. & Lipsett, M. B. Hypothalamic dysfunction in patients with anorexia nervosa. Medicine (Baltimore) 53, 147-159 (1974).
80. Kjeldsen, K. Hypokalemia and sudden cardiac death. Exp. Clin. Cardiol. 15, e96-e99 (2010).
81. American Psychiatric Association. Treatment of patients with eating disorders, third edition. American Psychiatric Association. Am. J. Psychiatry 163 (Suppl.), 4-54 (2006).
82. Fuentebella, J. & Kerner, J. A. Refeeding syndrome. Pediatr. Clin. North Am. 56, 1201-1210 (2009).
83. NHS Foundation Trust. Guideline for the management of refeeding syndrome (adults). NHS http://www.formulary.cht.nhs.uk/pdf,-doc-files-etc/MMC/089-Refeeding-Syndrome-3rd-Edition.pdf (2011).
84. Lawson, E. et al. Decreased nocturnal oxytocin levels in anorexa nervosa are associated with low bone mineral density and fat mass. J. Clin. Psychiatry 72, 1546-1551 (2011).
85. Lawson, E. A. et al. Postprandial oxytocin secretion is associated with severity of anxiety and depressive symptoms in anorexia nervosa. J. Clin. Psychiatry 74, e451-e457 (2013).
86. Sabatier, N. et al. α-melanocyte-stimulating hormone stimulates oxytocin release from the dendrites of hypothalamic neurons while inhibiting oxytocin release from their terminals in the neurohypophysis. J. Neurosci. 23, 10351-10358 (2003).
87. Zhang, Y. et al. Positional cloning of the mouse obese gene and its human homologue. Nature 372, 425-432 (1994).
88. Misra, M. et al. Secretory dynamics of leptin in adolescent girls with anorexia nervosa and healthy adolescents. Am. J. Physiol. Endocrinol. Metab. 289, E373-E381 (2005).
89. Exner, C. et al. Leptin suppresses semi-starvation induced hyperactivity in rats: implications for anorexia nervosa. Mol. Psychiatry 5, 476-481 (2000).
90. Hebebrand, J. et al. Leptin levels in patients with anorexia nervosa are reduced in the acute stage and elevated upon short-term weight restoration. Mol. Psychiatry 2, 330-334 (1997).
91. Holtkamp, K. et al. The effect of therapeutically induced weight gain on plasma leptin levels in patients with anorexia nervosa. J. Psychiatr. Res. 37, 165-169 (2003).
92. Misra, M. et al. Relationships between serum adipokines, insulin levels, and bone density in girls with anorexia nervosa. J. Clin. Endocrinol. Metab. 92, 2046-2052 (2007).
93. Pannacciulli, N. et al. Anorexia nervosa is characterized by increased adiponectin plasma levels and reduced nonoxidative glucose metabolism. J. Clin. Endocrinol. Metab. 88, 1748-1752 (2003).
94. Housova, J. et al. Serum adiponectin and resistin concentrations in patients with restrictive and binge/purge form of anorexia nervosa and bulimia nervosa. J. Clin. Endocrinol. Metab. 90, 1366-1370 (2005).
95. Tagami, T. et al. Adiponectin in anorexia nervosa and bulimia nervosa. J. Clin. Endocrinol. Metab. 89, 1833-1837 (2004).
96. Amitani, H. et al. The role of adiponectin multimers in anorexia nervosa. Nutrition 29, 203-206 (2013).
97. Kluge, M., Schossler, P., Uhr, M., Yassouridis, A. & Steiger, A. Ghrelin suppresses secretion of luteinizing hormone in humans. J. Clin. Endocrinol. Metab. 92, 3202-3205 (2007).
98. Kluge, M., Uhr, M., Bleninger, P., Yassouridis, A. & Steiger, A. Ghrelin suppresses secretion of FSH in males. Clin. Endocrinol. (Oxf.) 70, 920-923 (2009).
99. Otto, B. et al. Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Eur. J. Endocrinol. 145, 669-673 (2001).
100. Hotta, M., Ohwada, R., Akamizu, T., Shibasaki, T. & Kangawa, K. Therapeutic potential of ghrelin in restricting-type anorexia nervosa. Meth. Enzymol. 514, 381-398 (2012).
101. Karczewska-Kupczewska, M. et al. Increased suppression of serum ghrelin concentration by hyperinsulinemia in women with anorexia nervosa. Eur. J. Endocrinol. 162, 235-239 (2010).
102. Misra, M. et al. Elevated peptide YY levels in adolescent girls with anorexia nervosa. J. Clin. Endocrinol. Metab. 91, 1027-1033 (2006).
103. Utz, A. L. et al. Peptide YY (PYY) levels and bone mineral density (BMD) in women with anorexia nervosa. Bone 43, 135-139 (2008).
104. Lawson, E. et al. Appetite-regulating hormones cortisol and peptide YY are associated with disordered eating psychopathology, independent of body mass index. Eur. J. Endocrinol. 164, 253-261 (2011).
105. Nakahara, T. et al. Incomplete restoration of the secretion of ghrelin and PYY compared to insulin after food ingestion following weight gain in anorexia nervosa. J. Psychiatr. Res. 41, 814-820 (2007).
106. Misra, M. et al. Effects of anorexia nervosa on clinical, hematologic, biochemical, and bone density parameters in community-dwelling adolescent girls. Pediatrics 114, 1574-1583 (2004).
107. Faje, A. T. et al. Adolescent girls with anorexia nervosa have impaired cortical and trabecular microarchitecture and lower estimated bone strength at the distal radius. J. Clin. Endocrinol. Metab. 98, 1923-1929 (2013).
108. Lawson, E. A. et al. Hormone predictors of abnormal bone microarchitecture in women with anorexia nervosa. Bone 46, 458-463 (2010).
109. Walsh, C. J. et al. Women with anorexia nervosa: finite element and trabecular structure analysis by using flat-panel volume CT. Radiology 257, 167-174 (2010).
110. Rigotti, N. A., Neer, R. M., Skates, S. J., Herzog, D. B. & Nussbaum, S. R. The clinical course of osteoporosis in anorexia nervosa. A longitudinal study of cortical bone mass. JAMA 265, 1133-1138 (1991).
111. Solmi, M. et al. Bone mineral density, osteoporosis, and fractures among people with eating disorders: a systematic review and meta-analysis. Acta Psychiatr. Scand. 133, 341-351(2016).
112. Faje, A. T. et al. Fracture risk and areal bone mineral density in adolescent females with anorexia nervosa. Int. J. Eat. Disord. 47, 458-466 (2014).
113. Bredella, M. A., Misra, M., Miller, K. K., Klibanski, A. & Gupta, R. Trabecular structure analysis of the distal radius in adolescent patients with anorexia nervosa using ultra high resolution flat panel based volume CT. J. Musculoskelet. Neuronal Interact. 8, 315 (2008).
114. Van Coeverden, S. C. et al. Bone metabolism markers and bone mass in healthy pubertal boys and girls. Clin. Endocrinol. (Oxf.) 57, 107-116 (2002).
115. Soyka, L. A. et al. Abnormal bone mineral accrual in adolescent girls with anorexia nervosa. J. Clin. Endocrinol. Metab. 87, 4177-4185 (2002).
116. Westmoreland, P., Krantz, M. J. & Mehler, P. S. Medical complications of anorexia nervosa and bulimia. Am. J. Med. 129, 30-37 (2016).
117. Schneider, M., Fisher, M., Weinerman, S. & Lesser, M. Correlates of low bone density in females with anorexia nervosa. Int. J. Adolesc. Med. Health 14, 297-306 (2002).
118. Grinspoon, S. et al. Prevalence and predictive factors for regional osteopenia in women with anorexia nervosa. Ann. Intern. Med. 133, 790-794 (2000).
119. Miller, K. K. et al. Determinants of skeletal loss and recovery in anorexia nervosa. J. Clin. Endocrinol. Metab. 91, 2931-2937 (2006).
120. Abella, E. et al. Bone marrow changes in anorexia nervosa are correlated with the amount of weight loss and not with other clinical findings. Am. J. Clin. Pathol. 118, 582-588 (2002).
121. Bredella, M. A. et al. Increased bone marrow fat in anorexia nervosa. J. Clin. Endocrinol. Metab. 94, 2129-2136 (2009).
122. Fazeli, P. K. et al. Preadipocyte factor-1 is associated with marrow adiposity and bone mineral density in women with anorexia nervosa. J. Clin. Endocrinol. Metab. 95, 407-413 (2010).
123. Fazeli, P. K. et al. Marrow fat and preadipocyte factor-1 levels decrease with recovery in women with anorexia nervosa. J. Bone Miner. Res. 27, 1864-1871 (2012).
124. Ohlsson, C., Bengtsson, B. A., Isaksson, O. G., Andreassen, T. T. & Slootweg, M. C. Growth hormone and bone. Endocr. Rev. 19, 55-79 (1998).
125. Jia, D., O'Brien, C. A., Stewart, S. A., Manolagas, S. C. & Weinstein, R. S. Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology 147, 5592-5599 (2006).
126. Riggs, B. L. The mechanisms of estrogen regulation of bone resorption. J. Clin. Invest. 106, 1203-1204 (2000).
127. Mfdder, U. I. et al. Regulation of circulating sclerostin levels by sex steroids in women and in men. J. Bone Miner. Res. 26, 27-34 (2011).
128. Clarke, B. L. & Khosla, S. Androgens and bone. Steroids 74, 296-305 (2009).
129. Biller, B. et al. Mechanisms of osteoporosis in adult and adolescent women with anorexia nervosa. J. Clin. Endocrinol. Metab. 68, 548-554 (1989).
130. Lawson, E. A. et al. Plasma sodium level is associated with bone loss severity in women with anorexia nervosa: a cross-sectional study. J. Clin. Psychiatry 73, e1379-e1383 (2012).
131. Verbalis, J. G. et al. Hyponatremia-induced osteoporosis. J. Bone Miner. Res. 25, 554-563 (2010).
132. Sun, L. et al. Functions of vasopressin and oxytocin in bone mass regulation. Proc. Natl Acad. Sci. USA 113, 164-169 (2016).
133. Takeda, S. et al. Leptin regulates bone formation via the sympathetic nervous system. Cell 111, 305-317 (2002).
134. Cornish, J. et al. Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. J. Endocrinol. 175, 405-415 (2002).
135. Hamrick, M. W., Pennington, C., Newton, D., Xie, D. & Isales, C. Leptin deficiency produces contrasting phenotypes in bones of the limb and spine. Bone 34, 376-383 (2004).
136. Oshima, K. et al. Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. Biochem. Biophys. Res. Commun. 331, 520-526 (2005).
137. Shinoda, Y. et al. Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways. J. Cell. Biochem. 99, 196-208 (2006).
138. Wong, I. P. L. et al. Peptide YY regulates bone remodeling in mice: a link between gut and skeletal biology. PLoS ONE 7, e40038 (2012).
139. Klibanski, A., Biller, B. M., Schoenfeld, D. A., Herzog, D. B. & Saxe, V. C. The effects of estrogen administration on trabecular bone loss in young women with anorexia nervosa. J. Clin. Endocrinol. Metab. 80, 898-904 (1995).
140. Strokosch, G. R., Friedman, A. J., Wu, S.-C. & Kamin, M. Effects of an oral contraceptive (norgestimate/ethinyl estradiol) on bone mineral density in adolescent females with anorexia nervosa: a double-blind, placebo-controlled study. J. Adolesc. Health 39, 819-827 (2006).
141. Golden, N. H. et al. The effect of estrogen-progestin treatment on bone mineral density in anorexia nervosa. J. Pediatr. Adolesc. Gynecol. 15, 135-143 (2002).
142. Weissberger, A. J., Ho, K. K. & Lazarus, L. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. J. Clin. Endocrinol. Metab. 72, 374-381 (1991).
143. Misra, M. et al. Physiologic estrogen replacement increases bone density in adolescent girls with anorexia nervosa. J. Bone Miner. Res. 26, 2430-2438 (2011).
144. Miller, K. K. et al. Effects of risedronate and low-dose transdermal testosterone on bone mineral density in women with anorexia nervosa: a randomized, placebo-controlled study. J. Clin. Endocrinol. Metab. 96, 2081-2088 (2011).
145. Gordon, C. M. et al. Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: a randomized trial. J. Clin. Endocrinol. Metab. 87, 4935-4941 (2002).
146. Divasta, A. D. et al. The effect of gonadal and adrenal steroid therapy on skeletal health in adolescents and young women with anorexia nervosa. Metab. Clin. Exp. 61, 1010-1020 (2012).
147. Grinspoon, S., Thomas, L., Miller, K., Herzog, D. & Klibanski, A. Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa. J. Clin. Endocrinol. Metab. 87, 2883-2891 (2002).
148. Misra, M. et al. Effects of rhIGF-1 administration on surrogate markers of bone turnover in adolescents with anorexia nervosa. Bone 45, 493-498 (2009).
149. Golden, N. H. et al. Alendronate for the treatment of osteopenia in anorexia nervosa: a randomized, double-blind, placebo-controlled trial. J. Clin. Endocrinol. Metab. 90, 3179-3185 (2005).
150. Stathopoulos, I. P. et al. The use of bisphosphonates in women prior to or during pregnancy and lactation. Hormones (Athens) 10, 280-291 (2011).
151. Fazeli, P. K. et al. Teriparatide increases bone formation and bone mineral density in adult women with anorexia nervosa. J. Clin. Endocrinol. Metab. 99, 1322-1329 (2014).
152. Vahle, J. L. et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol. Pathol. 30, 312-321 (2002).
153. US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Guidance for industry. Development of parathyroid hormone for the prevention and treatment of osteoporosis. Draft guidance. FDA http://www.fda.gov/OHRMS/DOCKETS/98fr/001307gd.pdf (2000).
154. Herzog, W. et al. Outcome of bone mineral density in anorexia nervosa patients 11.7 years after first admission. J. Bone Miner. Res. 8, 597-605 (1993).
155. Hartman, D. et al. Bone density of women who have recovered from anorexia nervosa. Int. J. Eat. Disord. 28, 107-112 (2000).
156. Mueller, S. M. et al. Reduced bone strength and muscle force in women 27 years after anorexia nervosa. J. Clin. Endocrinol. Metab. 100, 2927-2933 (2015).
157. Misra, M. et al. Nutrient intake in community-dwelling adolescent girls with anorexia nervosa and in healthy adolescents. Am. J. Clin. Nutr. 84, 698-706 (2006).
158. Haagensen, A. L., Feldman, H. A., Ringelheim, J. & Gordon, C. M. Low prevalence of vitamin D deficiency among adolescents with anorexia nervosa. Osteoporos. Int. 19, 289-294 (2008).
159. Herzog, D. B., Nussbaum, K. M. & Marmor, A. K. Comorbidity and outcome in eating disorders. Psychiatr. Clin. North Am. 19, 843-859 (1996).
160. Miller, K. K. et al. Androgen deficiency: association with increased anxiety and depression symptom severity in anorexia nervosa. J. Clin. Psychiatry 68, 959-965 (2007).
161. Lund, T. D., Rovis, T., Chung, W. C. J. & Handa, R. J. Novel actions of estrogen receptor-β on anxiety-related behaviors. Endocrinology 146, 797-807 (2005).
162. Lawson, E. et al. Leptin levels are associated with decreased depressive symptoms in women across the weight spectrum, independent of body fat. Clin. Endocrinol. (Oxf.) 76, 520-525 (2012).
163. Gong, E. J., Garrel, D. & Calloway, D. H. Menstrual cycle and voluntary food intake. Am. J. Clin. Nutr. 49, 252-258 (1989).
164. Diz-Chaves, Y. et al. Behavioral effects of estradiol therapy in ovariectomized rats depend on the age when the treatment is initiated. Exp. Gerontol. 47, 93-99 (2012).
165. Milad, M. R., Igoe, S. A., Lebron-Milad, K. & Novales, J. E. Estrous cycle phase and gonadal hormones influence conditioned fear extinction. Neuroscience 164, 887-895 (2009).
166. Shores, M. M. et al. Increased incidence of diagnosed depressive illness in hypogonadal older men. Arch. Gen. Psychiatry 61, 162-167 (2004).
167. Lawson, E. A. et al. Oxytocin secretion is associated with severity of disordered eating psychopathology and insular cortex hypoactivation in anorexia nervosa. J. Clin. Endocrinol. Metab. 97, E1898-E1908 (2012).
168. Chui, H. T. et al. Cognitive function and brain structure in females with a history of adolescent-onset anorexia nervosa. Pediatrics 122, e426-e437 (2008).
169. Misra, M. et al. Impact of physiologic estrogen replacement on anxiety symptoms, body shape perception, and eating attitudes in adolescent girls with anorexia nervosa: data from a randomized controlled trial. J. Clin. Psychiatry 74, e765-e771 (2013).
170. Miller, K. K. et al. Effects of testosterone replacement in androgen-deficient women with hypopituitarism: a randomized, double-blind, placebo-controlled study. J. Clin. Endocrinol. Metab. 91, 1683-1690 (2006).
171. Miller, K. K. et al. Low-dose transdermal testosterone augmentation therapy improves depression severity in women. CNS Spectr. 14, 688-694 (2009).
172. Shifren, J. L. et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N. Engl. J. Med. 343, 682-688 (2000).
173. Misra, M. et al. Bone metabolism in adolescent boys with anorexia nervosa. J. Clin. Endocrinol. Metab. 93, 3029-3036 (2008).
174. Misra, M. et al. Percentage extremity fat, but not percentage trunk fat, is lower in adolescent boys with anorexia nervosa than in healthy adolescents. Am. J. Clin. Nutr. 88, 1478-1484 (2008).
175. Kapoor, D., Goodwin, E., Channer, K. S. & Jones, T. H. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur. J. Endocrinol. 154, 899-906 (2006).
176. Katznelson, L. et al. Using quantitative CT to assess adipose distribution in adult men with acquired hypogonadism. AJR Am. J. Roentgenol. 170, 423-427 (1998).
177. Katznelson, L. et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J. Clin. Endocrinol. Metab. 81, 4358-4365 (1996).
178. Wabitsch, M. et al. Serum leptin, gonadotropin, and testosterone concentrations in male patients with anorexia nervosa during weight gain. J. Clin. Endocrinol. Metab. 86, 2982-2988 (2001).
179. Rigotti, N. A., Neer, R. M. & Jameson, L. Osteopenia and bone fractures in a man with anorexia nervosa and hypogonadism. JAMA 256, 385-388 (1986).
180. Thienpont, E., Bellemans, J., Samson, I. & Fabry, G. Stress fracture of the inferior and superior pubic ramus in a man with anorexia nervosa and hypogonadism. Acta Orthop. Belg. 66, 297-301 (2000).
181. Sundgot-Borgen, J., Bahr, R., Falch, J. A. & Schneider, L. S. Normal bone mass in bulimic women. J. Clin. Endocrinol. Metab. 83, 3144-3149 (1998).
182. Naesson, S., Carlstrfm, K., Glant, R., Jacobsson, H. & Hirschberg, A. L. Bone mineral density in bulimic women - influence of endocrine factors and previous anorexia. Eur. J. Endocrinol. 155, 245-251 (2006).
183. Schorr, M. et al. Bone density, body composition, and psychopathology of anorexia nervosa spectrum disorders in DSM-IV versus DSM-5. Int. J. Eat. Dis. http://dx.doi.org/10.1002/eat.22603 (2016).